AroCell AB (publ) (AROC.ST)

SEK 0.59

(-2.33%)

Market Cap (In SEK)

134.99 Million

Revenue (In SEK)

43.03 Million

Net Income (In SEK)

-59.29 Million

Avg. Volume

224.71 Thousand

Currency
SEK
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.301-0.66
PE
-3.26
EPS
-0.18
Beta Value
1.267
ISIN
SE0003883990
CUSIP
-
CIK
-
Shares
230361000.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Mr. Anders Hultman B.Sc.
Employee Count
-
Website
https://www.arocell.com
Ipo Date
2011-05-25
Details
AroCell AB (publ), a vitro diagnostics company, focuses on monitoring of hematological malignancies, breast cancer, and other solid tumors. The company develops, manufactures, and sells AroCell TK 210 ELISA, an immunoassay kit for the determination of Thymidine Kinase 1 in human blood. It also offers TUBEX TF, a bacteriological rapid test for diagnosis of typhoid fever. The company was formerly known as Xi Bao Research AB and changed its name to AroCell AB (publ) in 2006. AroCell AB (publ) was incorporated in 2000 and is based in Uppsala, Sweden.